Table 1.

Patient, graft, and transplant characteristics

Factors	Frequency
Total number of patients	262
Age
Median (range)	44 (2–69)
Weight (kg)
Median (range)	78 (15–149)
Male	164 (63%)
Disease
Acute lymphoblastic leukemia	53 (20%)
Acute myeloid leukemia	99 (38%)
Chronic myeloid leukemia	12 (5%)
Myelodysplasia	21 (8%)
Chronic lymphocytic leukemia	9 (3%)
Non-Hodgkin lymphoma	38 (15%)
Hodgkin Lymphoma	19 (7%)
Juvenile myelomonocytic leukemia	5 (2%)
Multiple myeloma	6 (2%)
Disease risk
Standard	158 (60%)
High	104 (40%)
Prior autologous transplant	36 (14%)
HLA Match
4/6+4/6	94 (36%)
4/6+5/6	61 (23%)
4/6+6/6	4 (2%)
5/6+5/6	79 (30%)
5/6+6/6	11 (4%)
6/6+6/6	13 (5%)
ABO histocompatibility
Match, Match	52 (20%)
Match, Minor Mismatch	61 (23%)
Match, Major Mismatch	37 (14%)
Minor Mismatch, Minor Mismatch	40 (15%)
Minor Mismatch, Major Mismatch	39 (15%)
Major mismatch, Major Mismatch	30 (11%)
Missing	3 (1%)
Sex Match
Match, Match	52 (20%)
Match, Mismatch	145 (55%)
Mismatch, Mismatch	62 (24%)
Missing	3 (%)
Conditioning
Myeloablative: Cy/Flu/TBI1320 cGY	102 (39%)
Nonmyeloablative: Cy/Flu/TBI200 cGy	109 (42%)
Nonmyeloablative: Cy/Flu/TBI200 cGY/ATG	51 (19%)
Years to Last Contact (among survivors)
Median (range)	2.7 (0.5–7.2)

Cy: cyclophosphamide; Flu: fludarabine; TBI: total body irradiation; ATG: anti-thymocyte globuline.